IDEXX Laboratories (FRA:IX1) Total Liabilities : €1,642 Mil (As of Mar. 2024)

View and export this data going back to 1991. Start your Free Trial

What is IDEXX Laboratories Total Liabilities?

IDEXX Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 was €1,642 Mil.

IDEXX Laboratories's quarterly Total Liabilities declined from Sep. 2023 (€1,676.29 Mil) to Dec. 2023 (€1,628.04 Mil) but then increased from Dec. 2023 (€1,628.04 Mil) to Mar. 2024 (€1,641.84 Mil).

IDEXX Laboratories's annual Total Liabilities increased from Dec. 2021 (€1,546.28 Mil) to Dec. 2022 (€2,018.30 Mil) but then declined from Dec. 2022 (€2,018.30 Mil) to Dec. 2023 (€1,628.04 Mil).

IDEXX Laboratories Total Liabilities Historical Data

The historical data trend for IDEXX Laboratories's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

IDEXX Laboratories Total Liabilities Chart

IDEXX Laboratories Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

1,489.19

1,365.97

1,546.28

2,018.30

1,628.04

IDEXX Laboratories Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial															1,837.46	1,640.12	1,676.29	1,628.04	1,641.84

IDEXX Laboratories Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

IDEXX Laboratories's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	872.569	+	(662.582	+	60.087
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	32.799	+	0)
	=	1,628

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	2989.351	-	1361.314
	=	1,628

IDEXX Laboratories's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	880.35	+	(666.684	+	60.96
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	33.846	+	0)
	=	1,642

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	3085.234	-	1443.394
	=	1,642

IDEXX Laboratories Total Liabilities Related Terms

Thank you for viewing the detailed overview of IDEXX Laboratories's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

IDEXX Laboratories (FRA:IX1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » IDEXX Laboratories Inc (FRA:IX1) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

IDXX:USA IDXX:Mexico IX1:Germany I1DX34:Brazil IDXX:Austria

Address

One IDEXX Drive, Westbrook, ME, USA, 04092

Website

https://www.idexx.com

Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets close to 40% of its revenue from outside the United States.

IDEXX Laboratories (FRA:IX1) Headlines

No Headlines